vs
ARTIVION, INC.（AORT）与Resolute Holdings Management, Inc.（RHLD）财务数据对比。点击上方公司名可切换其他公司
Resolute Holdings Management, Inc.的季度营收约是ARTIVION, INC.的1.0倍（$117.7M vs $116.0M），ARTIVION, INC.净利率更高（2.1% vs -1.5%，领先3.5%），Resolute Holdings Management, Inc.自由现金流更多（$189.2M vs $-7.9M）
Artivion, Inc.是一家专注于心血管移植领域的医疗企业，主要供应经深低温冷冻保存的人体组织，同时研发各类医疗器械。旗下核心产品包括经过特殊处理、去除多余细胞物质与抗原的人体心脏瓣膜，以及BioGlue手术粘合剂，可为临床诊疗提供专业支持。
Resolute Holdings Management, Inc.是一家澳大利亚矿业企业，核心业务布局于非洲地区，目前运营两座金矿，分别为位于马里的 Syama 金矿和塞内加尔的 Mako 金矿，专注于黄金资源的勘探、开采及相关运营管理工作。
AORT vs RHLD — 直观对比
营收规模更大
RHLD
是对方的1.0倍
$116.0M
净利率更高
AORT
高出3.5%
-1.5%
自由现金流更多
RHLD
多$197.2M
$-7.9M
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $116.0M | $117.7M |
| 净利润 | $2.4M | $-1.7M |
| 毛利率 | 63.1% | 55.7% |
| 营业利润率 | 9.2% | 30.2% |
| 净利率 | 2.1% | -1.5% |
| 营收同比 | 19.2% | — |
| 净利润同比 | 114.7% | — |
| 每股收益（稀释后） | $0.06 | $-0.20 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AORTRHLD
| Q4 25 | $116.0M | $117.7M | ||
| Q3 25 | $113.4M | $120.9M | ||
| Q2 25 | $113.0M | $119.6M | ||
| Q1 25 | $99.0M | $103.9M | ||
| Q4 24 | $97.3M | — | ||
| Q3 24 | $95.8M | — | ||
| Q2 24 | $98.0M | — | ||
| Q1 24 | $97.4M | — |
净利润AORTRHLD
| Q4 25 | $2.4M | $-1.7M | ||
| Q3 25 | $6.5M | $-231.0K | ||
| Q2 25 | $1.3M | $-611.0K | ||
| Q1 25 | $-505.0K | $-3.4M | ||
| Q4 24 | $-16.5M | — | ||
| Q3 24 | $-2.3M | — | ||
| Q2 24 | $-2.1M | — | ||
| Q1 24 | $7.5M | — |
毛利率AORTRHLD
| Q4 25 | 63.1% | 55.7% | ||
| Q3 25 | 65.6% | 59.0% | ||
| Q2 25 | 64.7% | 57.5% | ||
| Q1 25 | 64.2% | 52.5% | ||
| Q4 24 | 63.2% | — | ||
| Q3 24 | 63.7% | — | ||
| Q2 24 | 64.6% | — | ||
| Q1 24 | 64.6% | — |
营业利润率AORTRHLD
| Q4 25 | 9.2% | 30.2% | ||
| Q3 25 | 11.1% | 34.3% | ||
| Q2 25 | 7.4% | 34.0% | ||
| Q1 25 | 2.2% | 24.7% | ||
| Q4 24 | 2.7% | — | ||
| Q3 24 | 4.6% | — | ||
| Q2 24 | 6.6% | — | ||
| Q1 24 | 26.0% | — |
净利率AORTRHLD
| Q4 25 | 2.1% | -1.5% | ||
| Q3 25 | 5.7% | -0.2% | ||
| Q2 25 | 1.2% | -0.5% | ||
| Q1 25 | -0.5% | -3.2% | ||
| Q4 24 | -16.9% | — | ||
| Q3 24 | -2.4% | — | ||
| Q2 24 | -2.2% | — | ||
| Q1 24 | 7.7% | — |
每股收益（稀释后）AORTRHLD
| Q4 25 | $0.06 | $-0.20 | ||
| Q3 25 | $0.13 | $-0.03 | ||
| Q2 25 | $0.03 | $-0.07 | ||
| Q1 25 | $-0.01 | $-0.39 | ||
| Q4 24 | $-0.40 | — | ||
| Q3 24 | $-0.05 | — | ||
| Q2 24 | $-0.05 | — | ||
| Q1 24 | $0.18 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $64.9M | $205.5M |
| 总债务越低越好 | $215.1M | $169.8M |
| 股东权益账面价值 | $448.2M | $6.5M |
| 总资产 | $884.8M | $333.4M |
| 负债/权益比越低杠杆越低 | 0.48× | 26.03× |
8季度趋势，按日历期对齐
现金及短期投资AORTRHLD
| Q4 25 | $64.9M | $205.5M | ||
| Q3 25 | $73.4M | $148.0M | ||
| Q2 25 | $53.5M | $99.9M | ||
| Q1 25 | $37.7M | $71.0M | ||
| Q4 24 | $53.5M | — | ||
| Q3 24 | $56.2M | — | ||
| Q2 24 | $55.0M | — | ||
| Q1 24 | $51.1M | — |
总债务AORTRHLD
| Q4 25 | $215.1M | $169.8M | ||
| Q3 25 | $214.9M | $173.4M | ||
| Q2 25 | $215.6M | $177.1M | ||
| Q1 25 | $314.7M | $180.7M | ||
| Q4 24 | $314.3M | — | ||
| Q3 24 | $314.0M | — | ||
| Q2 24 | $313.6M | — | ||
| Q1 24 | $313.3M | — |
股东权益AORTRHLD
| Q4 25 | $448.2M | $6.5M | ||
| Q3 25 | $438.7M | $10.8M | ||
| Q2 25 | $419.9M | $9.6M | ||
| Q1 25 | $294.3M | $8.9M | ||
| Q4 24 | $276.2M | — | ||
| Q3 24 | $304.7M | — | ||
| Q2 24 | $295.1M | — | ||
| Q1 24 | $295.0M | — |
总资产AORTRHLD
| Q4 25 | $884.8M | $333.4M | ||
| Q3 25 | $857.7M | $293.2M | ||
| Q2 25 | $838.4M | $253.3M | ||
| Q1 25 | $791.2M | $214.3M | ||
| Q4 24 | $789.1M | — | ||
| Q3 24 | $803.1M | — | ||
| Q2 24 | $789.5M | — | ||
| Q1 24 | $784.0M | — |
负债/权益比AORTRHLD
| Q4 25 | 0.48× | 26.03× | ||
| Q3 25 | 0.49× | 16.01× | ||
| Q2 25 | 0.51× | 18.42× | ||
| Q1 25 | 1.07× | 20.38× | ||
| Q4 24 | 1.14× | — | ||
| Q3 24 | 1.03× | — | ||
| Q2 24 | 1.06× | — | ||
| Q1 24 | 1.06× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $19.6M | $196.1M |
| 自由现金流经营现金流 - 资本支出 | $-7.9M | $189.2M |
| 自由现金流率自由现金流/营收 | -6.9% | 160.8% |
| 资本支出强度资本支出/营收 | 23.7% | 5.8% |
| 现金转化率经营现金流/净利润 | 8.06× | — |
| 过去12个月自由现金流最近4个季度 | $839.0K | $313.2M |
8季度趋势，按日历期对齐
经营现金流AORTRHLD
| Q4 25 | $19.6M | $196.1M | ||
| Q3 25 | $22.3M | $59.6M | ||
| Q2 25 | $15.0M | $48.9M | ||
| Q1 25 | $-17.0M | $18.4M | ||
| Q4 24 | $10.1M | — | ||
| Q3 24 | $11.5M | — | ||
| Q2 24 | $6.1M | — | ||
| Q1 24 | $-5.5M | — |
自由现金流AORTRHLD
| Q4 25 | $-7.9M | $189.2M | ||
| Q3 25 | $17.7M | $58.6M | ||
| Q2 25 | $11.7M | $47.5M | ||
| Q1 25 | $-20.6M | $17.8M | ||
| Q4 24 | $8.7M | — | ||
| Q3 24 | $7.8M | — | ||
| Q2 24 | $3.6M | — | ||
| Q1 24 | $-9.1M | — |
自由现金流率AORTRHLD
| Q4 25 | -6.9% | 160.8% | ||
| Q3 25 | 15.6% | 48.5% | ||
| Q2 25 | 10.4% | 39.7% | ||
| Q1 25 | -20.8% | 17.1% | ||
| Q4 24 | 9.0% | — | ||
| Q3 24 | 8.2% | — | ||
| Q2 24 | 3.7% | — | ||
| Q1 24 | -9.3% | — |
资本支出强度AORTRHLD
| Q4 25 | 23.7% | 5.8% | ||
| Q3 25 | 4.1% | 0.8% | ||
| Q2 25 | 2.9% | 1.2% | ||
| Q1 25 | 3.7% | 0.6% | ||
| Q4 24 | 1.5% | — | ||
| Q3 24 | 3.8% | — | ||
| Q2 24 | 2.6% | — | ||
| Q1 24 | 3.7% | — |
现金转化率AORTRHLD
| Q4 25 | 8.06× | — | ||
| Q3 25 | 3.42× | — | ||
| Q2 25 | 11.16× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -0.73× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AORT
| Aortic Stent Grafts | $43.3M | 37% |
| On X | $27.8M | 24% |
| Preservation Services | $24.1M | 21% |
| Surgical Sealants | $20.3M | 18% |
| Other Products | $463.0K | 0% |
RHLD
暂无分部数据
